| Followers | 4045 |
| Posts | 152977 |
| Boards Moderated | 3 |
| Alias Born | 08/05/2009 |
Wednesday, October 05, 2022 4:39:14 PM
WOW nice day was this a FWD split $150 to $7?
or was that the cliff dive from the news?
https://finance.yahoo.com/news/biohavens-als-drug-fails-meet-162405702.html
https://finance.yahoo.com/news/pfizer-completes-acquisition-biohaven-pharmaceuticals-170100256.html
https://ih.advfn.com/stock-market/NYSE/biohaven-BHVN/stock-news/89214155/biohaven-sets-new-course-with-258-million-in-cash
or was that the cliff dive from the news?
https://finance.yahoo.com/news/biohavens-als-drug-fails-meet-162405702.html
https://finance.yahoo.com/news/pfizer-completes-acquisition-biohaven-pharmaceuticals-170100256.html
https://ih.advfn.com/stock-market/NYSE/biohaven-BHVN/stock-news/89214155/biohaven-sets-new-course-with-258-million-in-cash
Recent BHVN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:17:29 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/04/2026 09:07:27 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/04/2026 08:23:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/04/2026 08:07:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:06:01 PM
- Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results • PR Newswire (US) • 05/04/2026 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:01:42 PM
- Biohaven Shares Edge Higher After Completing Enrollment in Obesity Drug Trial • IH Market News • 03/19/2026 02:12:23 PM
- Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment • PR Newswire (US) • 03/19/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/13/2026 08:57:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/13/2026 08:54:52 PM
- uniQure shares jump 36% after news of FDA gene therapy chief’s departure • IH Market News • 03/09/2026 02:14:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 09:32:34 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/02/2026 09:30:08 PM
- Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results • PR Newswire (US) • 03/02/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 04:19:08 PM
- Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/12/2026 04:15:00 PM
- Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 • PR Newswire (US) • 01/07/2026 12:00:00 PM
- Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder • PR Newswire (US) • 12/24/2025 06:00:00 PM
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress • PR Newswire (US) • 12/11/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:27:36 PM
- Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M • PR Newswire (US) • 11/13/2025 09:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/13/2025 12:09:09 PM
- Biohaven Announces Pricing of $175 Million Public Offering of Common Shares • PR Newswire (US) • 11/12/2025 12:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 11:02:50 AM

